Aptevo Therapeutics Inc Up 0.45% To $4.50 After Earnings Miss

Thursday, August 11, 2022 - Aptevo Therapeutics Inc (APVO) reported downside earnings and revenues today.

Aptevo Therapeutics Inc's earnings came in at an EPS loss of $1.82 per share, 37% lower than estimates for an EPS loss of $1.33 per share. The firm's loss per share expanded by 2% since reporting a loss of $1.78 per share a year ago. Remember, earnings reported were on an adjusted basis, so they may not be comparable to prior reports and/or analyst estimates.

Revenues were downbeat at $0.00. That represents a 0.00% decrease in revenues from the year-ago report and is 100.00% lower than consensus estimates set at $3.4 million.

The stock is up 0.45% to $4.50 after the report.

Despite Aptevo Therapeutics Inc reporting a decline in revenues, earnings increased signaling a rise in profit margins.

The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.

Trading in the five days leading up to the report earned Aptevo Therapeutics Inc a Neutral Sentiment Rank from InvestorsObserver.

Aptevo Therapeutics Inc has performed poorly during the past few months, garnering a low Long-Term Technical Rank by InvestorsObserver of 23, putting Aptevo Therapeutics Inc in the bottom 25% of stocks. The firm was recently trading at a 52-week low of $3.03 on June 15, 2022 and set a 52-week high on November 23, 2021 at $22.08.

Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.